Article Text

Download PDFPDF

Heated tobacco products: another tobacco industry global strategy to slow progress in tobacco control
  1. Stella A Bialous1,2,
  2. Stanton A Glantz3
  1. 1 Center for Tobacco Control, UCSF, San Francisco, California, USA
  2. 2 Social and Behavioral Sciences, School of Nursing UCSF, San Francisco, California, USA
  3. 3 Division of Cardiology, University of California, San Francisco, San Francisco, California, USA
  1. Correspondence to Dr Stella A Bialous, Center for Tobacco Control, University of California, San Francisco, CA 94143-1390, USA; stella.bialous{at}


There has been a global decline in tobacco consumption that, if continued, will negatively impact the tobacco industry’s profits. This decline led the industry to invent and market new products, including heated tobacco products (HTP). HTP are an extension of the industry’s strategies to undermine government’s tobacco regulatory efforts as they are being promoted as part of the solution for the tobacco epidemic. Under the moniker of ‘harm reduction’, the tobacco companies are attempting to rehabilitate their reputation so they can more effectively influence governments to roll back existing tobacco control policies or create exemptions for their HTP. Rolling back tobacco control policies will make it easier for the companies to renormalise tobacco use to increase social acceptability for all their products. When regulations are absent or when loopholes exist in classifying HTP as a tobacco product (thus subject to all tobacco control regulations), the industry’s marketing of HTP is making these products more visible to the public and more accessible. Governments need to ensure that HTP are regulated as tobacco products or drugs and reject partnerships with the tobacco companies to promote ‘harm reduction’. The tobacco companies remain the vector of the tobacco-caused epidemic and cannot be part of the global tobacco control solution.

  • tobacco industry
  • global health
  • non-cigarette tobacco products
  • public policy

This is an open access article distributed in accordance with the Creative Commons Attribution 4.0 Unported (CC BY 4.0) license, which permits others to copy, redistribute, remix, transform and build upon this work for any purpose, provided the original work is properly cited, a link to the licence is given, and indication of whether changes were made. See:

Statistics from

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.


  • Contributors Both authors participated in conceptualizing the paper, drafting and revising the manuscripts and approving the final, revised, draft.

  • Funding This study was funded by National Cancer Institute (grant number: CA- 087472), and Tobacco Related Disease Research Program Mackay Scholar Award.

  • Competing interests None declared.

  • Patient consent Not required.

  • Provenance and peer review Not commissioned; externally peer reviewed.